CBD reversed mitochondrial enlargement in Barth Syndrome cells, but not…

Cannabidiol abrogates the atypical enlargement of mitochondria in Tafazzin-deficient B-lymphoblastoid cells.

Biochemical and biophysical research communications • • Highly Relevant
🤖

AI Summary

This cell-based study asked whether cannabidiol (CBD) could change mitochondrial shape and dynamics in Tafazzin-deficient B-lymphoblastoid cells derived from people with Barth Syndrome. Using transmission electron microscopy, the researchers found that CBD reversed the cells’ unusually enlarged mitochondria, but did not significantly change the abnormal structure of their mitochondrial cristae.

The study also found that CBD fully reversed elevated phosphorylation of Drp1 at a site that inhibits mitochondrial fission, suggesting that changes in fission may help explain the reduced enlargement. These laboratory findings support a role for CBD in regulating mitochondrial dynamics, but the abstract does not establish a benefit in people with Barth Syndrome. It also cannot show whether the findings apply beyond these cultured cells; this is an abstract-based summary, not a review of the full paper.

💡 Key Findings

1
In Tafazzin-deficient B-lymphoblastoid cells, CBD reversed abnormal mitochondrial enlargement.
Good
70%
2
CBD had no significant effect on mitochondrial cristae architecture in the cells.
Good
70%
3
CBD fully reversed elevated phosphorylation of Drp1 at the fission-inhibitory Ser637 site, suggesting altered mitochondrial fission may be involved in the change in enlargement.
Good
65%

📄 Original Abstract

Barth Syndrome (BTHS) is a rare, X-linked disorder caused by the loss of function of Tafazzin, an enzyme responsible for the remodelling of cardiolipin. Although neutropenia is the best-characterized immunological deficit in BTHS, recent studies have also demonstrated deficiencies in B-cell and T-cell populations. BTHS patient-derived B-lymphoblastoid cells have been widely used to investigate the mitochondrial abnormalities associated with the disease. Our group, and others, have previously reported alterations in mitochondrial cristae architecture and the presence of abnormally enlarged mitochondria in these cells. Recently, we demonstrated that treatment of BTHS B-lymphoblastoids with the phytocannabinoid cannabidiol (CBD) restores maximal respiratory capacity, total cardiolipin content, the ratio of monolysocardiolipin to cardiolipin, and cell growth. However, the effects of CBD in restoring other mitochondrial parameters, including the relative abundance of various electron transport chain (ETC) proteins, and the profile of cardiolipin fatty acyl species, were ineffective or incomplete. Building on these findings, the present study aimed to examine whether CBD altered mitochondrial morphology and dynamics in Tafazzin-deficient B-lymphoblastoid cells. Using transmission electron microscopy, we found that CBD reversed the mitochondrial enlargement in BTHS B-lymphoblastoid cells but had no significant effect on cristae architecture. CBD fully reversed the elevated phosphorylation of Drp1 at the fission-inhibitory Ser637 site, strongly suggesting that the reduction in mitochondrial enlargement following CBD treatment involves the modulation of mitochondrial fission. Our results support the notion that cardiolipin composition, not just content, is important for mitochondrial ultrastructure in mammalian cells, and also supports a role for CBD in regulating mitochondrial dynamics.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.